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Abstract
Background: Hereditary nonpolyposis colorectal cancer
(HNPCC) is an autosomal dominant disorder predispos-
ing to predominantly colorectal cancer (CRC) and endo-
metrial cancer frequently due to germline mutations in
DNA mismatch repair (MMR) genes, mainly MLH1,
MSH2 and also MSH6 in families seen to demonstrate an
excess of endometrial cancer. As a consequence, tumors
in HNPCC reveal alterations in the length of simple repe-
titive genomic sequences like poly-A, poly-T, CA or GT
repeats (microsatellites) in at least 90% of the cases. Aim
of the Study: The study cohort consisted of 25 HNPCC
index patients (19 Amsterdam positive, 6 Bethesda posi-
tive) who revealed a microsatellite stable (MSS) – or low
instable (MSI-L) – tumor phenotype with negative muta-
tion analysis for the MMR genes MLH1 and MSH2. An
extended marker panel (BAT40, D10S197, D13S153,
D18S58, MYCL1) was analyzed for the tumors of these
patients with regard to three aspects. First, to reconfirm
the MSI-L phenotype found by the standard panel; sec-
ond, to find minor MSIs which might point towards an
MSH6 mutation, and third, to reconfirm the MSS status
of hereditary tumors. The reconfirmation of the MSS sta-
tus of tumors not caused by mutations in the MMR genes
should allow one to define another entity of hereditary
CRC. Their clinical features were compared with those of
150 patients with sporadic CRCs. Results: In this way, 17
MSS and 8 MSI-L tumors were reclassified as 5 MSS, 18
MSI-L and even 2 MSI-H (high instability) tumors, the last
being seen to demonstrate at least 4 instable markers out
of 10. Among all family members, 87 malignancies were
documented. The mean age of onset for CRCs was the
lowest in the MSI-H-phenotyped patients with 40.5 B 4.9
years (vs. 47.0 B 14.6 and 49.8 B 11.9 years in MSI-L-
and MSS-phenotyped patients, respectively). The per-
centage of CRC was the highest in families with MSS-
phenotyped tumors (88%), followed by MSI-L-pheno-
typed (78%) and then by MSI-H-phenotyped (67%) tu-
mors. MSS tumors were preferentially localized in the
distal colon supposing a similar biologic behavior like
sporadic CRC. MSH6 mutation analysis for the MSI-L and
MSI-H patients revealed one truncating mutation for a
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patient initially with an MSS tumor, which was reclassi-
fied as MSI-L by analyzing the extended marker panel.
Conclusion: Extended microsatellite analysis serves to
evaluate the sensitivity of the reference panel for HNPCC
detection and permits phenotype confirmation or up-
grading. Additionally, it confirms the MSS status of
hereditary CRCs not caused by the common mutations in
the MMR genes and provides hints to another entity of
hereditary CRC.
Copyright © 2004 S. Karger AG, Basel
Introduction
Hereditary nonpolyposis colorectal cancer (HNPCC)
is an autosomal dominant disease characterized by early
onset of colorectal, particularly right-sided, cancer (CRC).
It occurs with an incidence of up to 5% of all CRCs [1, 2].
Tumors in HNPCC reveal alterations in the length of sim-
ple repetitive genomic sequences like poly-A, poly-T, CA
or GT repeat (microsatellites) in at least 90% of the cases
[3]. This so-called microsatellite instability (MSI) is a con-
sequence of germline mutations within the DNA mis-
match repair (MMR) genes, mainly MSH2 [4], MLH1 [5],
and MSH6 [6], thus resulting in DNA replication errors.
In 1997, 126 mutations have been documented in a data-
base of the International Collaborative Group on
HNPCC in Leiden, The Netherlands [7]. Meanwhile, oth-
er novel mutations in the MMR genes have been detected
[8–11], so that more than 300 different predisposing
mutations are known to date. Genetically predisposed
individuals carry a defective copy of an MMR gene in
every cell. Somatic inactivation of the remaining wild-
type copy in a target tissue, typically colon, gives rise to a
profound repair defect, progressive accumulation of mu-
tations and cancer. The absence of MMR gene proteins
due to these mutations is also detectable by immunohisto-
chemical analysis with monoclonal antibodies [12, 13].
MSI, however, is not specific for HNPCC, but also
occurs in up to 16% of sporadic CRC [14, 15]. Additional-
ly, MMR gene mutations preferentially occur in cases of
MSI with at least 2 out of 5 markers [40%, so-called MSI-
high phenotype (MSI-H)], whereas they have rarely been
found in individuals with 1 out of 5 markers [20%, MSI-
low phenotype (MSI-L)] [16]. The most valid clinical
parameters for the prediction of an MSI-H phenotype and
occurrence of MMR gene mutations are the fulfilled Am-
sterdam criteria (AC) [17].
In our present study, we investigated 25 patients from
HNPCC families (19 Amsterdam positive, 6 Bethesda
Table 1. AC for HNPCC [19]
1 At least 3 family members with CRC, 2 of whom are first-degree
relatives
2 At least 2 consecutive generations affected
3 At least 1 individual less than 50 years old at diagnosis
4 Exclusion of familial adenomatous polyposis
Table 2. Bethesda criteria for HNPCC [20]
1 Individuals with cancer in families that meet the AC
2 Individuals with 2 HNPCC-related cancers, including syn-
chronous and metachronous CRCs or associated extracolonic
cancers
3 Individuals with CRC and a first-degree relative with CRC
and/or HNPCC-related extracolonic cancer and/or a colorectal
adenoma; 1 of the cancers diagnosed at age !45 years, and the
adenoma diagnosed at age !40 years
4 Individuals with CRC or endometrial cancer diagnosed at age
!45 years
5 Individuals with right-sided CRC with an undifferentiated
pattern (solid/cribriform) on histopathology diagnosed at age
!45 years
6 Individuals with signet-ring-cell-type CRC diagnosed at age
!45 years
7 Individuals with adenomas diagnosed at age !40 years
positive), who revealed microsatellite stable (MSS) or
MSI-L tumor phenotype in the 5 markers of the interna-
tional reference panel [18] with negative mutation analy-
sis for the common MMR genes MSH2 and MLH1 and
with normal immunohistochemical expression of the cor-
responding proteins.
Our purpose was, first, to reconfirm the MSI-L pheno-
type found by the standard panel, second, to find minor
MSIs which might point towards a MSH6 mutation, and
third, we wanted to reconfirm the MSS status of heredi-
tary tumors not caused by mutations in the MMR genes
and, in this way, define another entity of hereditary
CRC.
Patients and Methods
Patients
DNA samples were obtained from 25 consenting patients fulfill-
ing the AC or Bethesda criteria shown in tables 1 and 2 [19, 20].
Patients were recruited by genetic counseling or from the Depart-
ments of Gastroenterology and Surgery of the Universities of Mu-
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Table 3. Microsatellite markers of the expanded panel with their chromosomal location, repeat motif, primer sequences, annealing tempera-
ture and length of the amplification products
Name Chrom. loc. Repeat motif Primer sequence (5)–3)) PCR
temperature, °C 
Length, bp
BAT40 1p13.1 (T)7...(T)40 ATT AAC TTC CTA CAC CAC AAC
GTA GAG CAA GAC CAC CTT G
55 80–100
D10S197 10p12 (CA)7...(CA)12 ACC ACT GCA CTT CAG GTG AC
GTG ATA CTG TCC TCA GGT CTC C
58 161–173
D13S153 13q14 (CA)17 AGC ATT GTT TCA TGT TGG TG
CAG CAG TGA AGG TCT AAG CC
58 190–230
D18S58 18q22 (GC)5GA(CA)17 GCT CCC GGC TGG TTT T
GCA GGA AAT CGC AGG AAC TT
58 144–160
MYCL1 1p32 (GAAA)2...(GAAA)14 TGG CGA GAC TCC ATC AAA G
CTT TTT AAG CTG CAA CAA TTT C
55 140–209
BAT40 is a mononucleotide repeat, D10S197, D13S153 and D18S58 are dinucleotide repeats and MYCL1 is a tetranucleotide repeat.
Chrom. loc. = Chromosome location.
nich, Germany. In routine testing, their corresponding tumors were
analyzed with 5 markers of the international reference panel and
were judged to be MSS or MSI-L. Immunohistochemistry and muta-
tion analysis for MLH1 and MSH2 did not reveal a loss of expression
of the corresponding protein nor a disease-causing mutation in these
patients.
The clinical features like age at onset and tumor localization were
compared with 150 patients with sporadic CRC who are under regu-
lar surveillance in our gastroenterologic department.
Tumors
Tumors were judged macroscopically and microscopically by two
pathologists (G.B. and M.M.) including histologic examination (he-
matoxylin and eosin staining). Carcinomas were staged following the
TNM classification. They were graded in regard to their differentia-
tion (G1–4).
DNA Extraction
For the isolation of tumor DNA, blocks of surgically resected can-
cerous tissue that had been fixed in formalin and embedded in paraf-
fin were used. Regions of invasive cancer with the highest proportion
of neoplastic cells were microdissected (10-Ìm sections). DNA was
extracted by proteinase K digestion followed by repeated ethanol pre-
cipitation with gradual declining ethanol concentrations [21] using
the QIAmp Tissue Kit (Quiagen, Hilden, Germany). From the same
patients, DNA was isolated out of peripheral blood leukocytes by
using standard methods. Purified DNA was then quantified spectro-
photometrically before polymerase chain reaction (PCR).
Marker Selection
At first, the standard panel of 5 microsatellite markers (BAT25,
BAT26, D2S123, D5S346 and D17S250) was studied, which re-
vealed an MSI-L or MSS phenotype for all selected patients. Five
other microsatellite markers (BAT40, D10S197, D13S153, D18S58
and MYCL1) were then chosen. This panel is composed of 1 mono-
nucleotide, 3 dinucleotide and 1 tetranucleotide repeats. The se-
quences of the microsatellite PCR primers were taken as described
[22]. One member of each primer pair was labeled with a fluorescent
dye to permit detection by using an automated fluorescent DNA frag-
menting apparatus. Primer sequences are given in table 3.
Polymerase Chain Reaction
PCR was performed in a final volume of 20 Ìl containing 100 ng
DNA, 10 ! PCR buffer, 20 ÌM of each dNTP, 3 mM Mg2+, 30 pmol
of each primer and 1 U of Taq DNA polymerase (Master Mix, Quia-
gen). The DNA was amplified in a thermocycler (Biometra, Göttin-
gen, Germany) using a hot-start approach. PCR initially denatured at
94°C for 30 s, annealed at 55°C for 25 s for BAT40 and MYCL1, at
58°C for 25 s for D10S197, D13S153 and D18S58, with extension at
72°C for 1 min. The final extension after 35 cycles was performed at
72°C for 5 min and was followed by cooling to 4°C. Amplification
products were visualized by ethidium bromide staining in a 1.5%
agarose gel electrophoresis.
Fragment Analysis
PCR products were analyzed by a polyacrylamide/formamide gel
electrophoresis in a sequencing gel chamber (ABI PRISM 377 Genet-
ic Analyzer). Analysis was performed by a special software (PE
Applied Biosystems) and included determination of the length of the
PCR products and the height of the peaks. Amplification products
ranged between 80 and 230 base pairs.
MSI was defined by the presence of novel bands following PCR
amplification of tumor DNA, which were not present in PCR prod-
ucts of the corresponding normal DNA. To determine those markers
in which band shifts are difficult to interpret, all gels were evaluated
independently by two different observers (U.S. and E.H.-F.). Every
locus was scored as MSI or MSS.
Interpretation of MSI Phenotypes
A tumor was considered as having an MSI-H phenotype if at least
4 out of 10 markers (40%) exhibited band size shifts. Samples were
qualified as MSI-L phenotype if only up to 3 markers demonstrated
genetic alteration. Tumors without band shifts were reclassified as
MSS.
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Mutation Analysis for MSH2, MLH1 and MSH6
All exons of the MLH1 and MSH2 genes were amplified using
primers published previously [23, 24] with a touch-down PCR pro-
gram: 94°C for 5 min and first annealing at 63°C for 30 s, then a
progressive decrease in the annealing temperature by 1 °C each cycle
until the lowest annealing temperature of 50 °C, followed by synthe-
sis at 72°C for 30 s and then denaturation at 94°C for 30 s with
another 15 cycles at an annealing temperature of 50°C.
DHPLC analysis was carried out on an automated DHPLC
device equipped with a DNA separation column (WAVE: Transge-
nomic, San Jose, Calif., USA). Four to 7 Ìl of each PCR product
(containing 50–100 ng of DNA) was denatured at 95°C for 3 min.
The DNA strands were gradually reannealed by decreasing the sam-
ple temperature from 95 to 65°C over a period of 30 min. PCR prod-
ucts were then separated through a linear acetonitrile gradient (flow
rate 0.9 ml/min). The column mobile phase consisted of a mixture of
0.1 M triethylamine acetate (pH 7.0) with (buffer B) or without (buff-
er A) 25% acetonitrile. Gradient parameters were determined based
on the size and G-C content of the amplicon. Generally, analysis took
approximately 7 min, including column regeneration and re-equili-
bration to starting conditions. The temperature for the successful
resolution of heteroduplex molecules was determined by running
fragment-specific melting curves and by using the DHPLC melting
algorithm WAVE-MAKER of the wave instrument. Melting curves
were determined as follows: the elution time of a specific fragment
was determined under standard conditions. This specific gradient
was then tested with the same PCR product and temperatures rang-
ing from 48 to 70°C, and the retention time versus temperature was
plotted to yield a fragment-specific melting curve. These combined
results revealed an analysis temperature for each melting domain of
the fragment, which is optimal for 80–90% of the ·-helical fraction of
each domain.
Immunohistochemistry for MSH2 and MLH1
MSH2. Monoclonal mouse antihuman MSH2 antibody (Calbio-
chem Oncogene Research Products, Heidelberg, Germany) was used
at a dilution of 1:200. Two-micrometer sections of the paraffin-
embedded, formalin-fixed tissue blocks were pretreated by micro-
waving with target unmasking fluid (TUF, DAKO, Hamburg, Ger-
many) for 15 min at high power. The tissue was then incubated with
the primary antibody overnight at 4°C. Staining was visualized using
avidin-biotin complex (Vectastain Elite ABC-Kit, Vektor Labs,
Wertheim-Büttingen, Germany) with 3-amino-9-ethyl-carbazol
(AEC, Sigma, St. Louis, Mo., USA) and counterstaining was per-
formed with hematoxylin.
MLH1. Monoclonal mouse antihuman MLH1 antibody (Zymed,
Berlin, Germany) was used at a dilution of 1:80. Pretreatment was
done by microwaving with target unmasking fluid (TUF, DAKO) for
30 min at high power. Incubation was performed overnight at room
temperature, visualization was carried out using the Envision+ per-
oxidase complex (DAKO).
The staining pattern for both antibodies was nuclear. A negative
staining reaction in tumor cells was only regarded as a loss of protein
expression in the presence of a positive staining reaction in stromal
cells and lymphocytes which served as internal controls. Specificity
of staining was verified by replacement of the primary antibody with
the mouse IgG isotype (Southern Biotechnology Associates Inc., Bir-
mingham, UK), resulting in a negative staining reaction.
Statistics
Statistical evaluation between the tumor subgroups was per-
formed using the paired Student t test; p ! 0.05 was considered as
significant.
Results
The study published here was set out to further analyze
HNPCC families without MSI-H tumors and without dis-
ease-causing mutations in MLH1 and MSH2. An ex-
tended marker panel was analyzed, first, to receive addi-
tional information of a putative involvement of other
MMR genes, possibly resulting in a low degree of MSI that
was not detected by the standard panel; second, to recon-
firm the MSI-L phenotype for patients without mutations
in MLH1 and MSH2, and third, to reconfirm the MSS
status in order to gather hints towards another entity of
hereditary CRCs.
Extended MSI Analysis
The mean age of the 25 MSS, MLH1 and MSH2 muta-
tion-negative HNPCC patients (14 females, 11 males) was
46.1 B 12.9 years. An extended marker panel (BAT40,
D10S197, D13S153, D18S58, MYCL1) was analyzed for
the tumors of these patients regarding two aspects. First,
to confirm MSS and MSI-L tumors with an additional
marker set and second, to find MSI-L tumors, initially
judged as MSS, which then underwent MSH6 mutation
analysis. The extended marker panel includes one mono-
A-run (BAT40), 3 dinucleotide repeats (D10S197,
D13S153 and D18S58) and 1 tetranucleotide repeat.
The results of the microsatellite analysis with the
extended marker panel are summarized in table 4. In
total, 35 MSIs were found. From 17 original MSS tumors,
11 could now be reclassified as MSI-L (65%) and 1 even
as MSI-H (6%), whereas 5 were still seen to have an MSS
phenotype (29%). From 8 MSI-L tumors, 7 were still con-
sidered to be MSI-L (87%), but 1 was also found to be
MSI-H (13%). Both reclassified MSI-H tumors came
from Amsterdam-positive families. In summary, 17 MSS
and 8 MSI-L tumors were analyzed with an extended
marker panel and reclassified as 5 MSS, 18 MSI-L and 2
MSI-H tumors.
As an example, figure 1 shows the setting for the mark-
er BAT40 in a 55-year-old male HNPCC patient. In his
tumor DNA (lane below), novel bands in the amplifica-
tion product could be detected compared to the corre-
sponding genomic DNA (lane above).
The relative percentage of instability found for the sin-
gle markers was distributed fairly evenly with 9 tumors
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Fig. 1. Microsatellite analysis of the marker BAT40 (monocleotide repeat) in a 55-year-old male HNPCC patient.
Tumor DNA (lane below) reveals new bands and a band shift compared with the corresponding genomic DNA (lane
above).
400
300
200
100
0
5 Y : 05 BAT40  5086 / 5 R : 05 BAT40  5086 /
120
300
200
100
0
6 Y : 06 BAT40  5086T / 6 R : 06 BAT40  5086T /
Table 4. Age of onset, gender, tumor localization, clinical diagnosis and microsatellite status for the 5 reference markers BAT25, BAT26,
D5S346, D2S123, and D17S250 and 5 additional markers BAT40, D10S197, D13S153, D18S58 and MYCL1 in 25 MMS, MSH2 and MLH1
mutation-negative HNPCC patients
Patient
No.
Age Sex Tumor Diag-
nosis
BAT25 BAT26 D5S346 D2S123 D17S250 BAT40 D10S197 D13S153 D18S58 MYCL1 Status
1 57 m CRC AC s i s s s i s s i s MSI-L
2 35 f CRC AC s s s s s s s s s s MSS
3 46 f CRC AC s s s s s s s s s s MSS
4 42 f CRC AC s s s s s i s s s s MSI-L
5 51 f CRC AC s i s s s i LOH s i s MSI-L
6 50 m CRC AC s s s s s s s s i s MSI-L
7 38 m CRC BC s s s s s i s s i i MSI-L
8 37 f CRC AC s s i s s i i i s i MSI-H
9 45 m CRC AC s s s s s s s s s s MSS
10 47 m CRC AC s s s s s s s i s i MSI-L
11 44 f CRC AC s s s s s i i i s i MSI-H
12 44 f CRC AC s s s s s s s i s s MSI-L
13 57 m CRC AC s s s s s s s s s s MSS
14 39 f CRC BC s s s s s i i s s s MSI-L
15 44 m CRC BC s s s s s s i s i i MSI-L
16 60 f CRC AC s s s s s s s s i s MSI-L
17 5 f brain AC s s i s s s s s s s MSI-L
18 68 f sm. bow. BC s s s s i i s s s s MSI-L
19 38 m CRC BC s s s s i LOH s i s LOH MSI-L
20 66 m CRC BC s s s s s s s s s s MSS
21 48 f CRC AC s s s s s s s s s i MSI-L
22 44 f CRC AC s s s s s s s s i i MSI-L
23 64 f CRC AC s s s s s s s s s i MSI-L
24 38 m CRC AC s i s s s s i s s s MSI-L
25 69 f CRC AC s s s i s s s LOH i i MSI-L
BC = Bethesda criteria; s = stable; i = instable; sm. bow. = small bowel; LOH = loss of heterozygosity.
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Fig. 2. Distribution of MSI and MSS
of each additional microsatellite marker
among MSH2 and MLH1 mutation-nega-
tive HNPCC tumors.
Fig. 3. Mean age of HNPCC patients in
dependence on their microsatellite pheno-
types according to the extended panel of 10
markers in total. Patients with MSI-H tu-
mors were younger than patients with MSI
or MSS tumors. Mean age of patients with
sporadic CRC was significantly higher than
in all subgroups of HNPCC patients (p !
0.01).
(36%) being instable for MYCL1, 8 tumors (32%) for
BAT40 and D18S58, and 5 tumors (20%) for D13S153
and D10S197 (fig. 2).
Immunohistochemistry
All investigated tumors revealed a positive immuno-
histochemical reaction for MLH1 and MSH2 protein.
Mutation Analysis in MSH6
MSH6 mutation analysis for all patients with MSI-L
and MSI-H tumors revealed 1 truncating mutation in
exon 4 (c.1190–1191 del AG) for patient No.10 who was
diagnosed with CRC at the age of 47 years. His tumor was
judged as MSS with the reference panel and judged as
MSI-L after reevaluation with the extended marker panel.
Interestingly, his tumor did not show MSI for 1 of the 3
mono-A-runs analyzed here. The dinucleotide repeat
D18S58 and the complex repeat MYCL1 however
showed MSI for his tumor. Seven CRC cases were diag-
nosed among his first-degree relatives between 48 and 70
years of age. Six of the affected family members were
females, none of them had endometrial cancer.
Clinical Features: Tumor Localization and Age at
Onset
Subdividing the patients into three groups depending
on their reclassified MSI status, with 10 microsatellite
markers in total, some interesting clinical findings could
be revealed by evaluating 87 malignancies for the index
patients of the study cohort and their familiy members.
The mean age at onset was lowest in MSI-H tumors,
with 40.5 B 4.9 years, whereas it was higher in MSI-L
tumors, with 47.0 B 14.6 years, and was the highest in
MSS tumors with 49.8 B 11.9 years (fig. 3). There was no
difference in age between Amsterdam-positive (45.2 B
12.8 years) and Bethesda-positive (45.4 B 12.9 years)
families. The mean age at onset in sporadic CRC was sig-
nificantly higher with 64.9 B 11.1 years (p ! 0.01).
Among the MSI-H and MSI-L tumors, no clearly dom-
inant localization of the CRCs in regard to the splenic
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Fig. 4. The distribution of CRC localization
in dependence on the reclassified MSI status
of the MSH2 and MLH1 mutation-negative
HNPCC tumors. There was no clearly domi-
nant localization in regard to the splenic flex-
ure among the MSI-H and MSI-L tumors,
whereas MSS HNPCC tumors and sporadic
CRC occurred preferentially in the distal co-
lon.
Table 5. Occurrence of malignancies among
all index patients and family members of the
25 MSS, MSH2 and MLH1 mutation-nega-
tive HNPCC patients
Tumor MSI-H MSI-L MSS
Colorectal 6 47 16
Endometrial 0 4 0
Gastric 0 2 0
Brain 0 2 0
Urinary tract 0 1 1
Small bowel 0 1 0
Breast 0 1 0
Lung 0 0 1
Laryngeal 1 1 0
Leukemia 2 1 0
Total 9 60 18
flexure could be revealed (fig. 4). One of the MSI-H CRCs
was proximally, while the other was distally localized (50/
50%). Among the MSI-L tumors, 7 were recognized to be
proximal (43%), and 9 to be distal (57%) CRCs. However,
only 1 of the MSS tumors was proximal (20%), but 4 were
distal (80%) CRCs so that a preferential localization in
the distal colon of these tumors can be assumed (fig. 4).
Among sporadic CRC, tumors are seen to have occurred
proximal to the splenic flexure in 44 cases (29%) and in
the distal colon in 106 cases (71%).
Among the families of the MSS, MSH2 and MLH1
mutation-negative index patients, 87 affected family
members, including index patients, could be evaluated.
Examples of typical pedigrees are shown in figure 5a and
b. The occurrence of malignancies within these families is
given in table 5 (absolute numbers) and figure 6 (percent-
Fig. 5. a Pedigree of a 38-year-old female patient fulfilling the
Bethesda criteria without detectable MSH2 or MLH1 mutation.
An extended microsatellite analysis revealed an MSI-L phenotype.
b Pedigree of a 35-year-old female patient fulfilling the AC without
detectable MSH2 or MLH1 mutation. Even an extended microsatel-
lite analysis revealed an MSS phenotype. CRC was the only kind of
malignancy in this family.
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Fig. 6. Occurrence of malignancies among
all family members of the MSS, MSH2 and
MLH1 mutation-negative HNPCC patients.
The percent incidence of CRC was higher in
families of MSI-L- than MSI-H-phenotyped
patients (78 vs. 67%), and was highest in the
families with an MSS-phenotyped index pa-
tient (88%).
age). The percent incidence of CRC was higher in families
of MSI-L-phenotyped than in MSI-H-phenotyped pa-
tients (78 vs. 67%), and the highest in families with an
MSS-phenotyped index patient (88%), although the dif-
ferences between the tumor subgroups were not signifi-
cant (p = 0.19, 0.35 and 0.46, respectively).
Among Amsterdam-positive families, the percent inci-
dence of CRC was higher than in Bethesda-positive fami-
lies, but also without significance (81 vs. 74%).
Discussion
It is widely accepted that MSI assessment is a suitable
and cost-effective method in the diagnosis of HNPCC
[25]. In combination with immunohistochemistry, this
strategy has the potential to diagnose more than 90% of
tumors that involve alterations of the MSH2 and MLH1
gene [22]. Following the recommendation of the Interna-
tional Collaborative Group on HNPCC [18], we first
examined the reference panel of 5 microsatellite markers
in the 25 patients. Although in most cases even the AC for
HNPCC were fulfilled, which are considered to be highly
predictive for both, tumor instability and MMR gene
mutations [26], these index patients did not show muta-
tions in MSH2 and MLH1, nor did their tumors show a
loss of expression for the corresponding proteins. Micro-
satellite analysis revealed MSS tumors in 68% and low
instable tumors in 32% of the cases. To reconfirm the
MSS status or to reveal putative instabilities in other than
the recommended markers, we performed an extended
microsatellite analysis with 1 mononucleotide (BAT40), 3
dinucleotide (D10S197, D13S153, D18S58), and 1 te-
tranucleotide (MYCL1) repeats. These 5 microsatellites
were chosen since they had been shown to also be useful in
HNPCC screening [27–29]. Among them, especially
MYCL1 has been shown to have a relatively high instabil-
ity rate [22].
Due to an extended panel of microsatellite markers,
our data show that 2 tumors revealed an MSI-H pheno-
type (8%), which, in combination with a positive family
history (AC), is a very strong sign for cancerogenesis on
the MIN pathway.
Large genomic deletions, which occur in up to 12.6%
of patients meeting the AC [30], have not been excluded
for MSH2 and MLH1, as the tumors did not show aber-
rant immunohistochemical patterns for these proteins.
No MSH6 mutation was found for these 2 patients. This
points towards the possible involvement of other MMR
genes in the tumorigenesis within these families with
MSI-H tumors.
In fact, we detected 1 mutation in the MSH6 gene of a
47-year-old male patient with an initial MSS tumor that
was reclassified as MSI-L by analyzing the extended
marker panel. In this connection, several authors already
described MSH6 mutations and variants among patients
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with suspected HNPCC and MSI-L or MSS tumors, with
the restriction that these MSH6 mutations are rare in
families fulfilling the strong AC [16, 31]. The penetrance
of CRC appears to be significantly lower among MSH6
mutation carriers when compared with MSH2 and MLH1
mutation carriers (32 vs. 80%, by the age of 80 years) [32,
33]. An explanation may be that the loss of MSH6 causes
only a partial MMR defect leading to no or only low MSI
[34]. In addition, in vitro investigations revealed that cer-
tain MSH6 mutations do not affect MMR function [35].
All these findings underline the important value of the
MSH2 and MLH1 genes, and reveal that disease-causing
mutations are only rarely identified in any other MMR
genes in HNPCC [36].
Furthermore, 18 tumors could be reclassified as MSI-L
phenotype (72%), showing instability for 1–3 markers out
of 10, including tumors (16%) with 3 instable markers.
With regard to the international reference panel of 5
markers defining 1/5 instabilities (20%) as MSI-L, these
tumors with 3/10 instabilities (30%) were already margin-
ally of an MSI-H phenotype.
With the extended marker panel of microsatellites, 5
tumors were reconfirmed as being of an MSS phenotype
(20%). This finding hints to the supposition that these
tumors do not follow the MIN pathway, as they reveal
neither MSI nor causative mutations in the common
MMR genes MSH2 and MLH1. Genes, other than the
MMR genes might be disease-causing in these HNPCC
tumors.
With regard to the distribution of all malignancies in
HNPCC families, CRC has been shown to be the most
frequent tumor entity with up to 70%, while endometrial
carcinoma is observed in only 9% and gastric cancer in
only 6% of the cases [37]. Among the family members of
our selected patient group, CRC was even more frequent
with 69 of the 87 tumors (79.3%), whereas endometrial
carcinoma (4/87 = 4.6%) and gastric cancer (2/87 = 2.2%)
had a lower incidence as usual (table 4). Other tumors
which are not generally associated with HNPCC (laryn-
geal carcinoma, lung cancer, leukemia) occurred in quite a
considerable number of cases (6/87 = 6.9%; table 4).
Among CRCs of our patients, the total percentage of prox-
imal tumors (40%) was seen to be lower compared to
HNPCC data in the literature by up to 68% [37–39]. Con-
sequently, a higher frequency of distal CRC was detected.
Interestingly, this preferential localization was found
among the reclassified MSS tumors, whereas no domi-
nance of either proximal or distal CRC could be revealed
among the MSI-H- and MSI-L-phenotyped tumors.
Therefore, we suppose that these MSS tumors have a sim-
ilar biologic behavior to that of sporadic CRC, which is
known to be predominantly localized in the distal colon.
This phenomenon is emphasized by the fact that the
tumor spectrum in their families was clearly smaller (88%
CRC) than in the families of reclassified MSI-L patients,
which included different cancer manifestations.
The latter finding agrees with data of a recently pub-
lished study comparing Amsterdam-positive HNPCC pa-
tients with and without detectable MMR gene mutations
[40]. Among the mutation-negative patients, the authors
described a major subgroup with a later age at onset
(mean of 49.6 years), an abundance of distal CRC and
fewer HNPCC-related cancers. Similar results were pre-
sented by others revealing that HNPCC patients with
MMR gene mutations or MSI show an earlier age of onset,
more proximal CRC and the whole spectrum of tumor
manifestations known for MSI tumor disease as com-
pared to MSS, mutation-negative patients [41–43].
MSI-L tumors are difficult to define. On the one hand,
their tumor spectrum of affected family members points
to ‘classic HNPCC’, but the few MSIs and their mean age
at onset are difficult to be judged (47.0 B 14.6 vs. 40.5 B
4.9 years in MSI-H tumors). The detection of 1 MSH6
mutation for these patients underlines the sometimes
impaired MSI phenotype caused by proteins that do not
work in the ‘front line’, like MSH2 and MLH1. Immuno-
histochemistry and mutation analysis for these ‘second
line’ proteins and genes, like MLH3 and PMS2, need to
be performed.
In summary, we detected additional MSIs in an ex-
tended panel of markers among MSS, MSH2 and MLH1
mutation-negative HNPCC patients, including patients
who revealed MSS for BAT26, which is described to be
the most sensitive marker for MSI assessment [44, 45].
MSS or MSI-L phenotypes should not be considered as an
exclusion criterion for additional marker analysis or mu-
tation testing of MMR genes in general, above all if the
patients fulfill the strict AC, which are known to be the
best predictive clinical features for HNPCC due to muta-
tions in DNA MMR genes [46, 47].
Conclusions
(1) The upgrading of 2 tumors to MSI-H, which were
initially classified as MSI-L, points towards the involve-
ment of other MMR genes.
(2) The MSI-L tumors are difficult to define, however,
they might have a low penetrance instability not caused
by the analyzed MMR genes. These tumors need further
Extended Microsatellite Analysis in MSS,
MSH2 and MSH1 Mutation-Negative
HNPCC Patients
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immunohistochemical evaluation and mutation analysis
by including other tumors in these families as well.
(3) Five tumors (20%) did not show MSI. Their pre-
sumably hereditary tumors are not caused by mutations
in DNA MMR genes. Other genes that might classify
another entity of hereditary CRC may be involved. A first
indication for this is given by the clinical phenotype.
These families show a higher age at onset and mainly dis-
tally localized CRC with rare cancer occurrence outside
the gastrointestinal tract.
(4) One MSH6 mutation would have been missed by
the reference panel. In the extended marker panel, this
mutation did not result in an instability for mono-A-runs
either, in spite of the fact that this is the supposed func-
tion of MSH6. MSS tumors should be analyzed with an
extended marker panel, and in case of instability, should
be analyzed for MSH6.
To summarize, the analysis of an extended marker
panel, which is more accessible and available than MMR
genotyping, helps in the further classification of heredi-
tary CRC. Reclassification of phenotypes indicates the
clinical and biologic heterogeneity of HNPCC tumors.
Further research work to identify the disease-causing
genes will be necessary.
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